Proactive Investors - MGC Pharmaceuticals Ltd (LON:MXCM) is changing its name to Argent BioPharma Ltd and its ticker to RGT with the change to take effect from tomorrow, Wednesday, April 3, 2024.
The change was approved by shareholders at a general meeting on March 18, 2024, and has been processed by the Australian Securities and Investments Commission.
This milestone signals the conclusion of the company’s restructuring process and is supported by a substantial injection of capital and a comprehensive operational transformation.
“Well-positioned”
Subsequently, a new-look Argent BioPharma is set to position itself as a significant player in pioneering drug discovery within the biopharmaceutical sector.
With dual listings on the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is poised to make a considerable impact in advancing medical treatment accessibility, harnessing sophisticated methodologies in PolyPharmacology and Nanotechnology.
Argent BioPharma managing director and CEO Roby Zomer said: “As Argent BioPharma emerges from MGC Pharma, it is well positioned in the new era in biopharmaceuticals, committed to providing accessible and impactful healthcare solutions on a global scale.
“This rebranding signifies our commitment to innovation and advancement in the biopharmaceutical landscape.”
PolyPharmacology a key pillar
As a key pillar of Argent BioPharma’s philosophy, the company embraces PolyPharmacology, an innovative methodology focused on crafting and implementing therapeutics to influence numerous molecular targets simultaneously.
This approach plays a pivotal role in effectively tackling the intricacies of multifaceted diseases, thereby establishing a pioneering benchmark in drug development and therapeutic effectiveness.
Argent BioPharma places special emphasis on its product range targeting immunology and neurology, utilising PolyPharmacology to innovate novel treatments.
Committed to addressing unmet medical needs, the company aims to introduce new treatment every four years.
Key products include its Investigational Medicinal Products (IMPs) CannEpil® for refractory epilepsy and cerebral palsy, CimetrA® for acute lung injury and ARDS, and CogniCann® for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development.
Revenue generation
Argent BioPharma is positioned to generate revenue through CannEpil® and CimetrA®, which are accessible to patients through early access schemes in key markets including the UK, USA and Europe.
These initiatives are further supported by real-world data obtained from early access treatments, offering valuable insights into safety and efficacy that bolster clinical trial outcomes.
European research hub
Argent BioPharma’s European research hub is a key asset, playing a crucial role across the drug development continuum from conceptualisation to commercialisation and in this regard, the company adheres rigorously to stringent EU GMP and GDP guidelines.
This hub operates from two distinct manufacturing facilities - one dedicated to clinical trials and early access programs; and the other geared towards large-scale commercial production.
“We are excited to leverage our expertise in PolyPharmacology and Nanotechnology to pioneer ground-breaking treatments, addressing unmet medical needs and driving positive change in global healthcare,” Zomer added.
New website
The shareholdings of existing shareholders will not be affected by the change of name and existing share certificates should be retained as they will remain valid for all purposes and no new share certificates will be issued.
The company's website address is now www.argentbiopharma.com.